FMT
MYGN icon

First Mercantile Trust’s Myriad Genetics MYGN Stock Holding History

First Mercantile Trust’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,132
Closed -$330K – 879
2019
Q4 		$330K Sell
12,132
-790
-6% -$21.7K 0.04% 310
2019
Q3 		$370K Sell
12,922
-440
-3% -$12.8K 0.04% 302
2019
Q2 		$371K Buy
13,362
+3,109
+30% +$87.8K 0.04% 269
2019
Q1 		$340K Sell
10,253
-439
-4% -$13.4K 0.08% 295
2018
Q4 		$311K Sell
10,692
-764
-7% -$27.5K 0.08% 301
2018
Q3 		$527K Sell
11,456
-552
-5% -$24.5K 0.1% 240
2018
Q2 		$449K Sell
12,008
-553
-4% -$18.7K 0.09% 273
2018
Q1 		$371K Buy
12,561
+6,060
+93% +$205K 0.08% 318
2017
Q4 		$223K Sell
6,501
-1,067
-14% -$36K 0.04% 505
2017
Q3 		$274K Sell
7,568
-125
-2% -$3.56K 0.05% 471
2017
Q2 		$199K Sell
7,693
-2,235
-23% -$47.4K 0.04% 568
2017
Q1 		$191K Sell
9,928
-1,012
-9% -$17.9K 0.03% 589
2016
Q4 		$182K Sell
10,940
-6,947
-39% -$126K 0.03% 607
2016
Q3 		$368K Buy
17,887
+2,593
+17% +$65.8K 0.05% 455
2016
Q2 		$468K Sell
15,294
-94
-0.6% -$3.27K 0.06% 404
2016
Q1 		$576K Sell
15,388
-1,535
-9% -$57.8K 0.07% 343
2015
Q4 		$730K Sell
16,923
-3,702
-18% -$156K 0.07% 325
2015
Q3 		$772K Buy
20,625
+476
+2% +$16.9K 0.08% 325
2015
Q2 		$684K Sell
20,149
-5,285
-21% -$180K 0.06% 402
2015
Q1 		$900K Buy
25,434
+4,594
+22% +$164K 0.07% 343
2014
Q4 		$710K Sell
20,840
-756
-4% -$26.8K 0.06% 407
2014
Q3 		$833K Sell
21,596
-4,734
-18% -$177K 0.07% 383
2014
Q2 		$1.02M Buy
26,330
+4,270
+19% +$159K 0.08% 334
2014
Q1 		$754K Sell
22,060
-3,045
-12% -$94.3K 0.05% 472
2013
Q4 		$527K Sell
25,105
-1,765
-7% -$44.6K 0.04% 551
2013
Q3 		$631K Sell
26,870
-11,675
-30% -$332K 0.05% 509
2013
Q2 		$1.04M Buy
+38,545
New +$1.12M 0.09% 324

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Mercantile Trust's MYGN Position: Q1 2020 in Review

First Mercantile Trust sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 12,132 shares — an estimated $330K sold.

First Mercantile Trust first reported a position in MYGN in Q2 2013 and held it in 27 quarters. The position peaked at $1.04M in Q2 2013. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • First Mercantile Trust reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • First Mercantile Trust sold 12,132 Myriad Genetics shares in Q1 2020, an estimated $330K.
  • First Mercantile Trust first reported a position in Myriad Genetics in Q2 2013 and held it in 27 quarters.
  • First Mercantile Trust's Myriad Genetics position peaked at $1.04M in Q2 2013.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on First Mercantile Trust's 13F filing for Q1 2020, filed 12 May 2020.